Introduction: Boceprevir was not previously studied with peginterferon alfa-2a/ribavirin in
Results: The overall SVR12 rate was 81% (133/ 165, 95% confidence interval 74-86%). After 8 weeks of treatment, 61% of patients had
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INTRODUCTION
There are now several direct-acting antiviral agents (DAAs) from multiple classes available for the treatment of chronic hepatitis C [1] [2] [3] [4] [5] [6] [7] . In general, both interferon-free and interferon-containing DAA regimens increase sustained virological response (SVR) rates and allow for shorter treatment durations when compared with dual peginterferon/ribavirin therapy [1] [2] [3] [4] [5] [6] [7] . Access to these newer agents and combinations is restricted by the application of rigid patient selection criteria in most settings [2] . Dual peginterferon/ribavirin therapy is no longer recommended for genotype 1 patients by the European Association for the Study of Liver (EASL) and, as evidence of the rapid evolution of the field, boceprevir-based triple therapy is also not recommended unless more efficacious regimens are unavailable [4] .
Boceprevir was the first DAA approved for use in patients with chronic hepatitis C [8] . It is only indicated for use in combination with peginterferon/ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection and well-compensated liver disease [8] .
Treatment for 48 weeks with the combination of boceprevir plus peginterferon alfa-2b/ ribavirin produced an overall SVR rate (defined as undetectable HCV ribonucleic acid [RNA] levels for 24 weeks after the completion of therapy) of 66% in treatment-naïve patients in a large international registration trial (clinicaltrials.gov NCT01591460) [9] . However, the drug was not studied in combination with peginterferon alfa-2a/ribavirin during phase III trials in treatment-naïve patients. Safety was assessed by AE reports, physical and laboratory evaluations, and dosage adjustments and drug discontinuations.
Statistical Analysis
As this was an exploratory study, no formal hypothesis testing was involved. A sample size of approximately 150 patients was estimated to provide sufficient precision to assess the SVR rate in relation to that achieved with dual combination therapy (peginterferon alfa/ ribavirin) and triple combination therapy comprised a DAA plus peginterferon alfa/ ribavirin. This estimation was made on the basis of the SVR rate achieved with boceprevir plus peginterferon alfa-2b/ribavirin in a previous clinical trial (64-70%) which would provide a two-sided 95% confidence interval (CI) of ±8% [9] . The statistical analysis was performed with SAS version 8.2 and 9.2 (SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964. Informed consent was obtained from all patients for being included in the study.
RESULTS
A total of 165 patients were enrolled in Austria, Germany, Hungary, Poland, Romania, and Spain; the majority of patients were enrolled from Eastern European countries (70% in late responders) and a lower proportion of patients with a high baseline HCV RNA level in early responders (69% versus 88%, respectively).
The overall relapse rate was 7% (10/143) (CI 3-12%) (Fig. 3b) . All patients who relapsed harbored HCV genotype 1b and had a non-CC genotype (eight CT and two TT). Among patients with an early and late response the relapse rates were 4% and 9%, respectively, and among patients with cirrhosis the relapse rate was 13%. A C3-log 10 decrease in serum HCV RNA after 4 weeks of triple therapy (Week 8) was associated with both a positive predictive value and negative predictive value of 86% for SVR (Supplementary figure 3) . Rebound, defined as 1-log 10 increase above nadir, was observed in 6% (10/164) of patients with an on-treatment decrease in HCV RNA, and breakthrough was observed in 3% (4/151) of patients with an on-treatment virological response. Table 2) . Discontinuation of peginterferon alfa-2a, ribavirin, and boceprevir was attributed to neutropenia in 1, 1, and 4 patients, respectively, and to anemia in 0, 2, SD standard deviation, HCV hepatitis C virus, RNA ribonucleic acid * Cirrhosis or bridging fibrosis reported as ' 'cirrhosis or transition to cirrhosis''. Only patients with a fibrosis assessment are included in calculations. In two patients ' 'cirrhosis' ' was reported both on liver biopsy and noninvasive assessment (liver elastography) and 3 patients, respectively. A total of 10 patients (6%) received treatment with a hematopoietic stimulant (epoetin) and a total of 14 patients (8%) received treatment with a colony-stimulating factor. A total of five patients received transfusions of whole blood or packed red blood cells for anemia during the study.
The incidence of individual AEs was similar in the overall study population and in patients with cirrhosis (Table 2) . However, when compared with the overall study population, the incidence of SAEs was higher in cirrhotic patients as was the incidence of study drug discontinuation for AEs and of certain laboratory abnormalities (low hemoglobin concentrations and platelet count) ( Table 2 ). Of note, the incidence of thrombocytopenia was 12% overall (20/165), but was 33% (7/21) in patients with cirrhosis. Consistent with this observation, a higher proportion of cirrhotic patients had platelet counts of \50 9 10 9 /L (48% versus 8% in the overall study population).
DISCUSSION
The SVR12 rate observed in treatment-naïve patients treated with boceprevir plus peginterferon alfa-2a/ribavirin in this study was 81% overall. An overall SVR24 rate of 66%
was previously achieved with a 48-week fixed-duration regimen of boceprevir plus peginterferon alfa-2b/ribavirin in a large, randomized international registration trial (SPRINT-2, ClinicalTrials.gov Identifier:
b Fig. 3 SVR12 weeks after end of treatment (a) and relapse (b). ' 'Other' ' includes: one patient who did not stop treatment after fulfillment of futility rules; five patients who should have completed all therapy at Week 28, but instead received dual peginterferon alfa-2a/ ribavirin until Week 48; two patients who started boceprevir later than specified in the protocol (Study Days 54 and 43 rather than Study Day 29); six patients who discontinued treatment prematurely for reasons not related to futility rules and in whose cases information required to assign these patients to a response-guided therapy category is missing; and four patients who discontinued treatment prematurely according to futility rules and in whose cases information required to assign these patients to a response-guided therapy category is missing. Data for sustained virological response 24 weeks after end of treatment (SVR24) are not shown, but were almost identical to those for SVR12; only one patient who achieved an SVR12 did not achieve an SVR24 (due to missing data at week 24). IFN interferon, RGT response-guided therapy; SVR sustained virological response [9] . A direct comparison of the two trials is not possible, because the present trial included only patients from Central and Eastern Europe, whereas the SPRINT-2 trial included a substantial subgroup of Black patients (15%). Moreover, a higher proportion of patients in SPRINT-2 were infected with HCV genotype 1a (64% versus 13% in the present study). The SVR rate was lower in Black (53%) than non-Black patients (68%) in SPRINT-2 [9] . The frequency of important baseline characteristics predictive of SVR was similar in the present study and in the non-Black cohort in SPRINT-2 (19% and 12% of patients had bridging cirrhosis/cirrhosis, respectively, 77% and 84% of patients had a baseline HCV RNA [800,000 IU/mL, respectively, and the mean ages were 46 and 49 years, respectively) [9] .
Approximately one-half (47%) of patients enrolled in the present study had an early response, defined as undetectable HCV RNA at Weeks 8 and 24 of treatment. These patients were eligible to stop all therapy at Week 28, and importantly, all but two of these individuals completed the full 28-week regimen. The overall SVR12 rate in these individuals was 95%, which is comparable to that achieved with interferon-free DAA-containing regimens that are approved for use in patients with chronic HCV [1] [2] [3] [4] [5] [6] [7] . These results are important because access to interferon-free regimens is limited to patients who meet specific and restricted criteria in many jurisdictions [11] .
The overall SVR rate of 81% achieved with boceprevir plus peginterferon alfa-2a in the present study is comparable to SVR rates achieved in large Phase III studies of simeprevir-based triple therapy (QUEST-1, ClinicalTrials.gov Identifier: NCT01289782; QUEST-2, ClinicalTrials.gov Identifier:
NCT01290679) [12, 13] , and faldaprevir-based triple therapy (StartVerso-1, ClinicalTrials.gov Identifier: NCT01343888) (80-81%) [14] . It is not possible to draw any firm conclusions regarding the comparative efficacy of the different regimens used in these trials or between the present study and the phase III study by Poordad et al. [9] . Consistent with previous studies, anemia occurred frequently during boceprevir-based triple therapy. In the present study, a total of 41% of patients experienced anemia as an AE, 27% of patients had a hemoglobin concentration \100 g/L during treatment, and three patients discontinued treatment with boceprevir due to anemia. The incidence of anemia in the present study was similar to that reported in boceprevir recipients by Poordad et al. (49%) ; however, use of erythropoietin to treat anemia was less common in the present study than in the study by Poordad et al. (6% versus 43%) [9] .
Patients with cirrhosis are a particularly important subgroup of those with chronic hepatitis C, as they are at increased risk of hepatic decompensation, liver failure, and hepatocellular carcinoma. Boceprevir-based triple therapy produced an SVR12 in 67% of patients with compensated cirrhosis in the present study. Patients with a history or evidence of hepatic decompensation were excluded from this study in accordance with labeling for boceprevir and peginterferon alfa-2a. However, the incidence of SAEs, including anemia and thrombocytopenia, was somewhat higher in patients with cirrhosis than in non-cirrhotic patients, demonstrating that clinicians must monitor the former closely during treatment. The AE burden associated with boceprevir-based triple therapy is increased in patients with cirrhosis, and in particular, in those patients with cirrhosis in combination with a baseline platelet count \100,000/mm 3 and serum albumin level\35 g/ L [15] . Thus, careful patient selection is necessary when using boceprevir.
In an ideal world, every patient with chronic hepatitis C would have access to interferon-free regimens; in reality, this is restricted. In
Western Europe and North America, publicly funded treatment is available only for patients with advanced liver disease (e.g., Metavir F3-F4) [11] , while publicly funded treatment may not be available to any patient in other countries.
The first generation of protease inhibitors (PIs) (boceprevir and telaprevir) has been withdrawn from the market in the USA [1] , and these are rarely used in Western Europe. Where resources are limited, waiting is the only option as it may be some time before broad access to the new combinations is possible on a worldwide scale [16] . Resources are limited in most European countries, even in those that are economically well off, where (with the exception of France)
insurance companies restrict the use of interferon-free regimens to patients with advanced liver fibrosis (F3 and F4).
Notwithstanding guidance from EASL that boceprevir may need to be used in some settings with limited resources [4] , newer DAAs are preferred over first generation PIs, and thus, should be used where available.
Limitations of the TriCo study include the open-label design and the lack of a control group making it difficult to draw direct comparisons with randomized controlled trials in similar populations.
CONCLUSION
In conclusion, the results of this study demonstrate that an overall SVR rate of 81% can be achieved with the combination of boceprevir plus peginterferon alfa-2a/ribavirin in treatment-naïve patients with HCV genotype 1 infection that an SVR12 of 95% can be achieved in patients with an early response, and that treatment is well tolerated when the restrictions in the label are observed. 
